Abstract MicroRNAs (miRNAs) are small non-coding ribonucleic acids (RNAs) of approximately 22 bp that induce RNA interference with a complementary messenger RNA (mRNA) and act in silencing of mRNA. miRNAs are strongly associated with cancer development and those involved in carcinogenesis are classified into oncogenic miRNAs and tumor suppressor miRNAs (tumor suppressor miRs). Specific miRNAs are expressed in various tissues and changes in regulation of gene expression are thought to cause carcinogenesis. Thus, tissue-specific miRNAs may be biomarkers for cancer diagnosis and prognosis. Approaches to application of miRNAs as cancer therapy are also ongoing, based on the involvement of miRNAs in carcinogenesis. In endometrial cancer, miRNAs are associated with regulation of gene expression, epigenetic dysfunction and carcinogenesis. Thus, miRNAs are likely to have key roles in diagnosis, prognostic prediction, and therapy in endometrial cancer.
Introduction
A microRNA (miRNA) is a small non-coding ribonucleic acid (RNA) molecule of approximately 22 bases that targets a messenger RNA (mRNA) with a complementary sequence for gene silencing. miRNAs regulate mRNA levels through posttranslational, transcriptional and posttranscriptional mechanisms, with the best-known mechanism being RNA interference (RNAi), which occurs posttranscriptionally [1] . A miRNA has several hundred target genes and all mRNAs are regulated by miRNAs. miRNAs are produced from DNA and transcribed to primary miRNA (pri-miRNA), which then forms precursor miRNA (pre-miRNA). pre-miRNA is further transformed to double-stranded miRNA (ds miRNA) and then to mature single-stranded miRNA (ss miRNA). This miRNA is incorporated into the RNA-induced silencing complex (RISC), which then forms the bioactive miRNAinduced silencing complex (miRISC). mRNAs that are negatively regulated by miRISC are transferred to a processing body (P-body) and degraded. miRNAs with a fully complementary sequence to a target mRNA degrade the corresponding mRNA, while miRNAs with partial complementary sequences repress translation of mRNA (Fig. 1) .
MicroRNAs in carcinogenesis
miRNAs are associated with development of tumors as oncogenic miRNAs (oncomiRs) and tumor suppressor miRNAs (tumor suppressor miRs). An oncomiR acts as an oncogene and has increased expression in tumor cells, while a tumor suppressor miR acts as a tumor suppressor gene and has decreased expression in tumor cells (Fig. 2) . Involvement of miRNAs in carcinogenesis has been of interest since it was found that miRNAs have different expression patterns in different tissues and that expression levels change significantly in cancer tissues in comparison with normal tissue [2] . OncomiRs and tumor suppressor miRs promote carcinogenesis and miRNAs have also been linked to proliferation, invasion, epithelial-mesenchymal transition (EMT), and metastasis of tumor cells.
Epigenetic effects are involved in the relationship of miRNAs to carcinogenesis. Multiple patterns of cancer induction may be present because tumor suppressor miRs are themselves affected by epigenetic regulation, in addition to their epigenetic regulation of oncogenes or tumor suppressor genes [1, 3] . For example, miR-34a is a tumor suppressor miR involved in carcinogenesis through epigenetic regulation. miR-34a expression is decreased in pancreatic cancer cells, as well as in breast, ovarian, colorectal, and lung cancer cells. This is thought to be due to miRNA epigenetic silencing, since miR-34a expression is recovered by epigenetic modification through addition of 5-aza-2 0 -deoxy cytidine (5-Aza-dC), a demethylating agent, and suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in pancreatic cancer cells with decreased miR-34a expression. These results suggest that 5-Aza-dC and SAHA are candidate anticancer agents [4] . miR-34b and miR-34c also result in carcinogenesis in colorectal cancer due to epigenetic silencing, with hypermethylation of CpG islands close to miR-34b/c resulting in decreased expression of these miRNAs [5] . In lung cancer, miR-34b/c methylation is significantly increased in small cell lung cancer in comparison with non-small-cell lung cancer [6] .
Decreased expression of miR-139 occurs in colorectal cancer and is an indicator of advanced cancer and poor survival [7] . This suggests that a reduced level of miRNA expression is linked to the severity of cancer. In contrast, miR-17-92a and miR-106b-25 are oncomiRs with hyperexpression in lung and colon cancer, lymphoma, multiple myeloma and medulloblastoma (miR-17-92a); and gastric, colon and prostate cancer, neuroblastoma and multiple myeloma (miR-106b-25). These two miRNAs induce carcinogenesis by silencing expression of transforming growth factor-b receptor type 2 (TGFBR2), Sma-and Madrelated protein 2 (SMAD2), and bone morphogenetic protein (BMP) family genes [8] .
Relationships of miRNAs with cancer stem cells (CSCs) have also recently emerged. These cells are specific inducers of growth and development in tumor tissues and are defined as cells with self-proliferative and differential capacity and the potential to transform normal cells. miRNAs may determine the direction of differentiation in CSC, and miRNA dysregulation produces CSCs and leads to carcinogenesis [4] . Mammary CSCs (CD44 ? / CD24 low/-) have decreased expression of the let-7 miRNA family (let-7a, let-7b, let-7d, let-7f, let-7i) on chromosome 9 [9] , while expression of miR-451 is significantly decreased in colorectal cancer [10] . miR-451 targets the macrophage migration inhibitory factor (MIF) gene, which regulates expression of cytochrome oxidase subunit 2 (COX-2). COX-2 activates the Wnt/b-catenin pathway and enhances growth of CSCs. Therefore, hypoexpression of miR-451 may contribute to carcinogenesis of colorectal cancer through enhancement of growth of CSCs. A relationship of miRNA with carcinogenesis has also been found in pancreatic cancer with a poor prognosis. miR-101 in pancreatic cancer cells regulates mRNA of several cancer cell markers, including Nanog, SRY-related highmobility group box 2 (SOX2), and octamer-binding transcription factor 4 (Oct4), suggesting involvement in CSCs.
In general, these findings suggest that miRNAs have important roles in CSC growth and proliferation in various tissues [4] .
MicroRNAs as biomarkers for cancer diagnosis
Current tumor markers used in clinical applications are mainly fragments of cancer cell-derived glycoproteins in blood. These markers can be measured simply and with low invasiveness, and provide a useful indicator of the tumor status. However, some tumor markers have low specificity, resulting in a loss of diagnostic accuracy. In contrast, miRNAs have various expression patterns and different expression profiles in normal and cancer tissues. These patterns can be used as biomarkers for cancer diagnosis. miR-21 is a well-studied oncomiR that is hyperexpressed in many cancers. The blood levels of miR-21 in patients with breast, esophageal, gastric, rectal, and lung cancer differ significantly from those in healthy volunteers, and the sensitivity and specificity of miR-21 are higher than those of conventional tumor markers, suggesting that miR-21 may be a useful biomarker for cancer diagnosis. However, miR-21 is detected in multiple cancer tissues and this may reduce specificity for detection of primary lesions. Thus, supplemental diagnostic imaging using CT and MRI is needed for effective use of miR-21 as a cancer biomarker, but miRNAs still reduce the need for costly tests due to their higher sensitivity and specificity compared to other tumor markers [11] . miRNAs are also applicable as potential biomarkers for early detection of pancreatic cancer. An analysis of blood from patients with pancreatic cancer and healthy volunteers showed that expression of 7 miRNAs (miR-20a, miR-21, miR-24, miR-25, miR-99a, miR-185, and miR-191) correlated with the cancer stage, and miR-21 showed a marked correlation with survival. Furthermore, expression of these 7 miRNAs was not detected in patients with chronic pancreatitis, indicating that these miRNAs may be useful for differentiation between these cancers [12] . miRNAs are also likely to be useful for prediction of prognosis and survival. For example, recurrence and mortality have been found to be significantly higher in patients with Stage III colorectal cancer with miR-608 expression, while miR-219-1 is an indicator of mortality in colorectal cancer [13] . These two miRNAs are correlated only with survival and are ineffective for detection of the development of cancer [14] . In lung adenocarcinoma, survival has been correlated with 5 miRNAs (hsa-miR-155, hsa-miR1703p, hsa-let-7a-2, hsa-miR-145, and hsa-miR-21), with hyperexpression of hsa-miR-155 and hypoexpression of hsa-let-7a-2 being particularly good prognostic indicators [15] . In patients with glioma, those with decreased expression of miR-335 have significantly lower survival compared with those with normal expression of miR-335, suggesting that miR-335 is an effective prognostic biomarker [16] . In esophageal squamous cell carcinoma, miR133a, a tumor suppressor miR for CD47, has similarly been suggested to be a biomarker for predicting progression and prognosis [17] .
MicroRNAs in cancer therapy
miRNAs may be of value in cancer therapy, as well as in diagnosis. An antisense oligonucleotide complementary with a target miRNA can be used. These methods both require administration of exogenous miRNA. However, artificial exogenous miRNAs may have different kinetics from endogenous miRNA, and delivery and stability in vivo also need to be addressed.
There are several methods for administration of exogenous miRNA. In mice, adenovirus-mediated delivery of miR-34a resulted in enhanced expression of the miRNA in the cerebellum and an antitumor effect. Studies using stable nucleic acid-lipid particles (SNALPs) have shown transfer of miRNA to target tissues and a similar antitumor effect to that found using adenovirus. Use of a polyurethane-short branch polyethylenimine (PU-PEI) permitted uptake of miR-145 into glioblastoma CD133
? cells and suppression of differentiation of these cells into CSCs. Use of an MS2 bacteriophage capsid for miRNA delivery has also been proposed. Development of these approaches will permit delivery of miRNAs to target cells and promotion of antitumor activity, and to date no toxicity or adverse events have been found in animal models [4] .
Wang et al. showed that miRNAs form complex networks in vivo and that some miRNAs have positive and negative effects in carcinogenesis. This finding resulted in proposal of cassette dosing as a new miRNA therapy, in which multiple exogenous miRNAs are delivered simultaneously. Using this strategy, three miRNAs with 2 0 -methoxyphosphorothioate modifications (2 0 -MeOPS-miR-16-1, 2 0 -MeOPSmiR-29b, 2 0 -MeOPS-antagomiR-155) were intravenously administered through injection into target organs and shown to have bioactivity. This suggests that cassette dosing is a promising therapeutic approach for miRNA application [18] .
Therapeutic applications of miRNAs include actions beyond direct antitumor effects due to inhibition or supplementation. Thus, application of miRNA is currently being evaluated to decrease drug resistance. Treatment of glioblastoma CD133
? cells with PU-PEI-miR-145 reduced drug resistance and increased sensitivity to radiation and temozolomide [19] . In a study in SKOV3 cells collected from cisplatin-resistant ovarian cells and SKOV3/CIS cells, expression of miR-130a, which targets the phosphatase and tensin homolog (PTEN) gene, was enhanced in SKOV3/CIS cells. Reduction of expression of miR-130a regulated the expression of multidrug resistance protein 1 (MDR1) and P-glycoprotein mRNAs, leading to reduced cisplatin resistance in SKOV3/CIS cells [20] . In breast cancer, miR-203 is also involved in cisplatin resistance. Knockdown of miR-203 after treatment with cisplatin enhanced expression of p53, p21 and Bax proteins and led to cisplatin-sensitive apoptosis in MCF-7 breast cancer cells. One target of miR-203 is the suppressors of cytokine signaling 3 (SOCS3) gene, and enhanced expression of SOCS3 in MCF-7 cells has recently been shown by application of an anti-miR-203 agent [21] .
These studies show that cancer chemotherapy using miRNAs can be performed based on various mechanisms of action and has many potential effects. However, it is unclear whether exogenous miRNAs will have equivalent effects to those of endogenous miRNAs [22] .
MicroRNAs in the endometrium
The endometrium cyclically proliferates and sheds under the influence of estrogen (estradiol-17b) and progesterone. Tumor suppression by miRNAs is important because of the frequent cell proliferation in the endometrium. In a comparison of miRNA expression patterns in the proliferative and secretion phases, Kuokkanen et al. identified 12 miRNAs (miR-29b, miR-29c, miR-30b, miR-30d, miR-31, miR-193a-3p, miR-203, miR-204, miR-200c, miR-210, miR-582-5p, and miR-345) with enhanced expression in the mid-term secretion phase that suppressed expression of genes involved in the cell cycle, including cyclin and cyclin-dependent kinase, and E2F transcription factor 3 (E2F3) [23, 24] . This study shows that miRNAs regulate cell proliferation in the endometrial secretion and proliferation phases by regulating the cell cycle.
Toloubeydokhti et al. found 32 miRNAs with characteristic expression levels in the mesometrium and granulosa cell epithelium, including 8 (miR-20a, miR-21, miR-23, miR-26a, miR-18a, miR-181a, miR-206, and miR-142-5p) regulated by estradiol-17b and progesterone. These miRNAs regulated the expression of TGF-b, estrogen and progesterone receptors, and aromatase (CYP-19A1), with important physiological consequences in the endometrium [25] . A recent study has also indicated a relationship of miR-20a with the ectopic endometrium, i.e., endometriosis [26] . Thus, miR-20a expression is markedly enhanced in ectopic endometrial cells, in comparison with normal endometrial cells. miR-20a suppresses expression of dual-specificity phosphatase-2 (DUSP2) and induces hyperexpression of elk-related tyrosine kinase (ERK)-related genes [early growth response protein (EGR-1), cysteine-rich angiogenic inducer 61 (CYR61) and osteopontin]. ERK-related genes are involved in angiogenesis and endometrial proliferation, and thus miR-20a may induce endometriosis due to hyperexpression of these genes [26] . In addition, angiogenesis is activated and ectopic endometrial cells are induced under hypoxic conditions in the endometrium, and hyperexpression of miR20a in ectopic endometrial cells is also caused by hypoxic stress. This indicates the important role of miR-20a in the development of endometriosis.
A comparative study of miR-135a expression levels in ectopic and normal endometrial cells showed increased expression of miR-135a by about threefold in ectopic cells, which suggests that miR-135 is also involved in endometriosis [27] . Expression of miR-135a is particularly significantly increased in the proliferation phase during the menstrual cycle. Expression of miR-135b is slightly higher in normal endometrial cells regardless of the menstrual cycle, but is enhanced in endometriotic cells, particularly in the proliferation and secretion phases. miR-135a/b also regulate the expression of homeobox A1 (HOXA1) in endometriotic cells, which suggests that these miRNAs are involved in the mechanism of development of endometriosis [27] .
MicroRNAs and endometrial cancer
Enhanced and regulated expression of miRNAs has recently been associated with carcinogenesis in endometrial cancer [28] [29] [30] . miR-185, miR-106a, miR-181a, miR210, miR-423, miR-103, miR-107, miR-let7c, miR-205, miR-449, and miR-429 show enhanced expression in endometrial cancer tissues compared with normal tissues, whereas miRlet7e, miR-221, miR-30c, miR-152, miR-193, miR204 miR-99b, and miR-193b have decreased expression in cancer tissues (Table 1) .
The role of miRNAs in development of endometrial cancer is thought to involve DNA methylation. High expression of the SRY-related high-mobility group box 4 (SOX4) gene is found in endometrial cancer cells [31] and SOX4 is negatively regulated by miR-129-2. Epigenetic regulation through DNA demethylation and histone acetylation enhances expression of miR-129-2 and strongly reduces downstream SOX4 expression, resulting in regulation of overgrowth in endometrial cancer cells. miR-129-2 is also thought to be involved in microsatellite instability and methylation of human mutL homolog 1 (hMLH1), a DNA mismatch repair (MMR) gene involved in development of type I endometrial cancer. hMLH1 is methylated at high levels in endometrial cancer tissues, and this induces mutation of other oncogenes including human mutS homolog 6 (hMSH6), type II transforming growth factorbeta (TGF-bII), Bcl2-associated X protein (BAX), and PTEN; therefore, this methylation may play an important role in the early phase of carcinogenesis [32] .
Expression of miR-152 is also thought to be regulated by DNA methylation [34] . DNA methyltransferase 1 (DNMT1), E2F3, met proto-oncogene (MET) and rapamycin-insensitive companion of mTOR (Rictor) are all target genes of miR-152. DNMT is an enzyme that methylates DNA, E2F3 is an E2F family transcriptional inhibitor and an oncogene, and MET is a well-known oncogene. Rictor interacts with mammalian target of rapamycin complex 2 (mTORC2), regulates phosphorylation in the Akt signal pathway, and is involved in carcinogenesis. Since miR-152 regulates expression of many genes involved in carcinogenesis, therapy with miR-152 may be a novel approach for treatment and prevention of endometrial cancer, and miR-152 might also be useful as a biomarker for early detection [32, 33] .
Several miRNAs are potential prognostic indicators in endometrial cancer, including miR-125b. Of the two types of endometrial cancer, the type II form has a poor prognosis and no precancerous lesion. miR-125b expression is significantly elevated in type II endometrial cancer cells in comparison with type I cells. One target of miR-125b is the tumor protein p53 inducible nuclear protein 1 (TP53INP1) gene, and dysfunctional regulation of this gene by miR125b enhances proliferation and release of cancer cells and may be associated with the severity of type II endometrial cancer [34] . A second target gene of miR-125b, V-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), is associated with enhanced invasion in endometrial cancer cells [35] .
miR-30c suppresses cell proliferation of human endometrial cancer-derived cell lines (Ishikawa and HEC1B cells) by regulating metastasis-associated gene-1 (MTA1) [36] and is thought to be involved in both type I and II endometrial cancer. miR-30c suppresses phenomena that lead to a poor prognosis, such as overgrowth, metastasis and invasion of endometrial cancer cells, and therefore may be useful in therapy, as well as a prognostic biomarker [37] . miR-204 also regulates endometrial metastasis and invasion [38] . One of the target genes of miR-204 is Forkhead box C1 (FOXC1), which regulates metastasis and invasion in human endometrial cancer-derived HEC1A cells. In endometrial cancer, decreased expression of miR-204 causes dysfunctional regulation of FOXC1, which results in enhanced metastasis and invasion of tumor cells. Therefore, miR-204 is also a potentially useful prognostic biomarker [38] .
miR-205 expression targeting PTEN is significantly correlated with decreased survival in endometrial cancer, and thus miR-205 is also a potential prognostic biomarker [39] . miR-194 regulates BMI-1 expression by binding to the 3 0 -UTR of the B lymphoma Mo-MLV insertion region 1 homolog (BMI-1) oncogene. BMI-1 is an important negative prognostic factor due to induction of the EMT and enhanced cancer metastasis. miR-194 suppresses metastasis by regulating BMI-1 and local monoclonal cell proliferation due to p16 hyperexpression and decreased expression of SOX2, Krueppel-like factor 4 (KLF4) and multidrug resistance-associated protein 1 (MRP-1) [40] .
Endometrial serous adenocarcinoma is classified as a type II cancer with a poor prognosis and frequent involvement of p53. A total of 6 miRNAs show expression patterns specific to serous adenocarcinoma, with miR-34b being the most important. miR-34b suppresses proliferation, migration and invasion of cancer cells and the promotor region of miR-34b is methylated in serous adenocarcinoma [41] .
The relationships between endometrial cancer and miRNAs also extend to treatment resistance. Thus, the levels of miR-200b, miR-200c and miR-429 are elevated in endometrial cancer and show positive correlations with resistance to cisplatin. The target of these miRNAs is AP-2a and overexpression of this gene causes resistance to [28] miR-106a miR-221 Wu et al. [29] miR-181a miR-30c Chung et al. [30] cisplatin. Interestingly, the rs1045385A[C SNP weakens the connection of resistance to miR200b/200c/42. This suggests that a SNP search may permit selection of appropriate chemotherapy for patients and have high clinical significance [42] .
Conclusions
Many miRNA analyses have been conducted in patients with gastrointestinal and breast cancer, and there are now many studies of miRNAs in endometrial cancer. miR-129-2 and miR-152 are involved in development of endometrial cancer via DNA methylation and many miRNAs, including miR-125b, miR-30c, miR-194 and miR-34b, are expressed in endometrial cancer tissue and regulate proliferative, metastatic and invasive activities. miRNAs involved in carcinogenesis are currently targets for early detection and cancer prevention and may be highly specific diagnostic biomarkers. Other miRNAs, including miR-125b, miR-30c, miR-200b/c and miR-429, are related to resistance to cisplatin and may be prognostic biomarkers for endometrial cancer. All miRNAs can theoretically be regulated by administration of exogenous miRNAs, which suggests that miRNAs will emerge as therapeutic agents; however, the safety and efficacy of exogenous miRNA is unknown and these agents have yet to be used clinically. Further establishment of the roles of miRNAs in endometrial cancer may permit personalized early diagnosis and therapy.
